FDA Recalls Budesonide Extended-Release Tablets for Failed Dissolution
FDA has recalled approximately 10,672 bottles of Budesonide Extended-Release Tablets 9mg manufactured by Teva Pharmaceuticals due to failed dissolution specifications.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall involving a manufacturing defect that creates risk of harm—failed dissolution can result in inadequate delivery of a medication patients depend on for treating serious inflammatory conditions. Although no illnesses or injuries have been reported, the defect affects core drug functionality.
Plain-English summary
Teva Pharmaceuticals USA, Inc. has issued a nationwide recall of Budesonide Extended-Release Tablets 9mg (NDC 0591-2510-30, Lot # 100047273, expiration 07/2025). The recall affects approximately 10,672 bottles in the 30-count package size. The tablets failed to meet FDA dissolution specifications, meaning they may not dissolve properly in the digestive system, potentially resulting in inadequate drug delivery.
Budesonide is a prescription corticosteroid used to treat inflammatory bowel diseases such as Crohn's disease. When tablets fail to dissolve as intended, patients may not receive the full therapeutic dose required for their condition. No illnesses or injuries have been reported at this time.
Patients taking this medication should contact their pharmacist or healthcare provider to determine whether their supply includes tablets from the recalled lot. Do not stop taking budesonide without consulting a healthcare professional, as abrupt discontinuation of corticosteroids can have serious health consequences. Patients with affected medication should obtain a replacement supply from their pharmacy.
The recalled product
- Product
- BUDESONIDE (BUDESONIDE)
- Brand
- BUDESONIDE
- Manufacturer
- Teva Pharmaceuticals USA, Inc
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 100047273
- Exp. 07/2025
UPCs (1)
- 0305912510303
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · BUDESONIDE
- HighBudesonide inhalation ampules contain black and brown specks and particles
FDA (Drugs) · 2026-06-17
- HighBudesonide inhalation ampoules recalled after leakage and empty ampoule complaint
FDA (Drugs) · 2025-07-30
- HighInhalation Drug Recalled Due to Sterility Assurance Failure
FDA (Drugs) · 2022-10-05
Same manufacturer · Teva Pharmaceuticals USA, Inc
See all →- SevereOctreotide Acetate Injectable Suspension Recalled Due to Sterility Assurance
FDA (Drugs) · 2026-05-13
- ModerateClaravis isotretinoin 10 mg capsules recalled for out-of-specification impurity
FDA (Drugs) · 2026-04-29
- ModerateTeva clonidine 0.2 mg patches recalled over unapproved raw material use
FDA (Drugs) · 2026-04-15
- HighTeva isotretinoin 30 mg capsules recalled as superpotent and subpotent
FDA (Drugs) · 2026-04-15
- HighTeva isotretinoin 40 mg capsules recalled as superpotent and subpotent
FDA (Drugs) · 2026-04-15
Same hazard · failed dissolution
See all →- ModerateNovartis Recalls Diovan Valsartan Tablets Due to Failed Dissolution Specifications
FDA (Drugs) · 2026-08-19
- LowSupernus Recalls Trokendi XR Capsules for Failed Dissolution Specifications
FDA (Drugs) · 2026-07-29
- HighAscend amlodipine and olmesartan tablets failed dissolution specifications
FDA (Drugs) · 2026-06-10
- HighLannett niacin extended-release tablets failed dissolution specifications during stability
FDA (Drugs) · 2026-06-10
- HighMajor Pharmaceuticals memantine extended-release capsules fail dissolution specifications
FDA (Drugs) · 2026-04-22